Introduction
Skin fungi diseases are a common group of skin diseases caused by fungi, including beakheads, gills, gills, bracelets, platinum, acetals, etc., with a high incidence and a certain degree of infectiousness, which seriously affects the quality of life and physical and mental health of patients. Primary health-care institutions play a key role in the prevention and treatment of dermal fungi as the front line of health services. It is important to know the status of their treatment and to look ahead to the future.
II. Status of treatment
(i) Diagnostic aspects
Traditional fungi screening methods, such as direct lenses, are now widely used in primary health-care institutions. Doctors observe the presence of filaments or spores under microscopes by scratching specimens such as scabs on the edges of the patient ‘ s skin, scabs and scabs, which are simple and inexpensive, but which require a high level of experience of the tester and have a certain rate of failure due to factors such as the location of the body, the method and the quality of the specimen. Cultivation, while relatively high in accuracy, takes a long time and usually takes days to weeks to obtain results, to the detriment of timely diagnosis and treatment.
(ii) Therapeutic drugs
There is a relatively limited range of external antigen drugs available for use at the grass-roots level, including, inter alia, titanium (e.g., ketamex, titamex), acetamine (e.g., Tebitrin cream). These drugs have some effect on mild skin fungi diseases, such as limited thorium, gills, etc., but the effects of purely exterior medication are often less than desirable for fungi diseases that are more severe, widespread or cumbersome, and special areas such as nails. Oral anti-facter drugs, such as Ictarconoxin and Tebbiphine, although their effects are significant in the treatment of persistent or deep skin fungi diseases, their lack of knowledge by primary doctors about their drug use indicators, dosage adjustments and adverse-response monitoring has led to inadequate and widespread application at the grass-roots level.
(iii) Patient education
There are shortcomings in the education of patients at the primary level. Many patients have little knowledge of the causes of skin fungi disease, the route of transmission, the course of treatment and the prevention of relapse, and fail to properly understand the severity of the disease and the importance of maintaining treatment. Some patients stop taking their own medications after a slight reduction in symptoms, which leads to repeated cases, increases the difficulty of treatment and the cost of medical treatment, and also contributes to the spread of the disease within families and communities.
III. Challenges
First, there is insufficient professional training of medical staff at the primary level, slower updating of knowledge of dermal pathology, lags in knowledge of new anti-fist drugs and diagnostic techniques, and difficulties in making accurate diagnosis and rational treatment decisions in the face of complex or unusual skin fungi diseases. Second, the poor hardware facilities in primary health-care institutions and the lack of advanced fungi detection equipment, such as fluorescent microscopes, fungi culture automation systems and molecular biology diagnostic instruments, limit the accuracy and timeliness of diagnosis. Moreover, the relative scarcity of primary health-care resources and the sometimes difficult availability of medicines to meet clinical needs, in particular, the inadequate availability of new and special-effect anti-foulbacterial drugs, have affected treatment effectiveness.
IV. Outlook for the future
The treatment of skin fungi in primary health-care institutions is expected to open up new opportunities for development as medical technology progresses and basic health-care reforms deepen. With regard to diagnostic techniques, new, rapid, simple and accurate diagnostic methods, such as Proximity Test (POCT) based on nucleic acid amplification, will be available to detect fungal pathogens in a short period of time, improve diagnostic efficiency and provide a basis for early precision treatment. At the same time, an ingenious skin mirror examination combined with an artificially intelligent assistive diagnostic system can help grass-roots doctors to identify more accurately the characterization of skin fungal disease and reduce errors and omissions.
In the field of drug treatment, new anti-facter drugs will be available, with greater efficacy, safety and ease of delivery, and it is expected that they will be adapted through health-care policy to improve accessibility at the primary level. In addition, through the establishment of a regional medical consortium or tele-medicine collaboration network, doctors at the grass-roots level have access to real-time guidance and training of dermal specialists at higher-level hospitals to improve their level of treatment. At the same time, the provision and quality control of drugs in primary health-care institutions is being strengthened to ensure an adequate and effective supply of anti-fist drugs to meet the treatment needs of patients.
In the future, the treatment of dermal fungi will move towards precision, standardization and efficiency, providing better quality and accessible medical care to a large number of patients, effectively controlling the spread and harm of dermal fungal disease and promoting the overall advancement of primary health care.